GM-CSF Combined with Low-Dose Cytosine Arabinoside: A Trial Proposed for High-Risk Myelodysplastic Syndromes and Results of a Dose-Finding Study

Myelodysplastic Syndromes ◽

10.1007/978-3-642-75952-9_46 ◽

1992 ◽

pp. 321-329

Author(s):

H. H. Gerhartz ◽

H. Schmetzer ◽

B. Wolf-Hornung ◽

A. C. Stern

Keyword(s):

High Risk ◽

Myelodysplastic Syndromes ◽

Cytosine Arabinoside ◽

Low Dose ◽

Dose Finding ◽

Gm Csf ◽

Finding Study ◽

Dose Finding Study

Download Full-text

Faculty Opinions recommendation of Luspatercept for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes (PACE-MDS): a multicentre, open-label phase 2 dose-finding study with long-term extension study.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.730774358.793564974 ◽

2019 ◽

Author(s):

Anna Rita Migliaccio

Keyword(s):

Myelodysplastic Syndromes ◽

Lower Risk ◽

Dose Finding ◽

Extension Study ◽

Phase 2 ◽

Open Label ◽

Finding Study ◽

Open Label Phase ◽

Dose Finding Study

Download Full-text

Low-dose subcutaneous ketamine for postoperative pain management in Rwanda: a dose-finding study

Canadian Journal of Anesthesia/Journal canadien d anesthésie ◽

10.1007/s12630-017-0914-0 ◽

2017 ◽

Vol 64 (9) ◽

pp. 928-934 ◽

Cited By ~ 6

Author(s):

Jon Tuchscherer ◽

William P. McKay ◽

Theogene Twagirumugabe

Keyword(s):

Pain Management ◽

Postoperative Pain ◽

Low Dose ◽

Postoperative Pain Management ◽

Dose Finding ◽

Finding Study ◽

Dose Finding Study

Download Full-text

Luspatercept for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes (PACE-MDS): a multicentre, open-label phase 2 dose-finding study with long-term extension study

The Lancet Oncology ◽

10.1016/s1470-2045(17)30615-0 ◽

2017 ◽

Vol 18 (10) ◽

pp. 1338-1347 ◽

Cited By ~ 125

Author(s):

Uwe Platzbecker ◽

Ulrich Germing ◽

Katharina S Götze ◽

Philipp Kiewe ◽

Karin Mayer ◽

...

Keyword(s):

Myelodysplastic Syndromes ◽

Lower Risk ◽

Dose Finding ◽

Extension Study ◽

Phase 2 ◽

Open Label ◽

Finding Study ◽

Open Label Phase ◽

Dose Finding Study

Download Full-text

The effects of the addition of low-dose dopamine on renal and cardiac function in septic critically-ill patients: A dose finding study

Intensive Care Medicine ◽

10.1007/bf01921247 ◽

1996 ◽

Vol 22 (S1) ◽

pp. S73-S73 ◽

Cited By ~ 1

Author(s):

M T Patten ◽

B V McCloskey ◽

J H Zwaveling ◽

A R J Girbes

Keyword(s):

Cardiac Function ◽

Critically Ill ◽

Critically Ill Patients ◽

Low Dose ◽

Dose Finding ◽

Finding Study ◽

Dose Finding Study

Download Full-text

Chloroprocaine 10 mg/ml for low-dose spinal anaesthesia in perianal surgery - a randomised dose finding study

Acta Anaesthesiologica Scandinavica ◽

10.1111/aas.12839 ◽

2016 ◽

Vol 61 (2) ◽

pp. 241-249 ◽

Cited By ~ 7

Author(s):

V. Gebhardt ◽

L. Mueller-Hansen ◽

A. Schwarz ◽

D. Bussen ◽

C. Weiss ◽

...

Keyword(s):

Spinal Anaesthesia ◽

Low Dose ◽

Dose Finding ◽

Finding Study ◽

Dose Finding Study

Download Full-text

(F7) Randomized phase II study with GM-CSF and low-dose ARAC in patients with “high risk” myelodysplastic syndromes

Leukemia Research ◽

10.1016/0145-2126(91)90376-5 ◽

1991 ◽

Vol 15 ◽

pp. 14

Keyword(s):

High Risk ◽

Phase Ii ◽

Myelodysplastic Syndromes ◽

Low Dose ◽

Phase Ii Study ◽

Gm Csf ◽

Randomized Phase Ii

Download Full-text

Low-Dose Interleukin 2 in Children with Recently Diagnosed Type 1 Diabetes: A Phase 1/2 Randomised, Double-Blind, Placebo-Controlled Dose Finding Study

SSRN Electronic Journal ◽

10.2139/ssrn.3384899 ◽

2019 ◽

Author(s):

Randa Salet ◽

Michelle Rosenzwajg ◽

Roberta Lorenzon ◽

Alexandra Roux ◽

Jean Claude Carel ◽

...

Keyword(s):

Type 1 Diabetes ◽

Low Dose ◽

Phase 1 ◽

Interleukin 2 ◽

Dose Finding ◽

Double Blind ◽

Double Blind Placebo ◽

Finding Study ◽

Dose Finding Study

Download Full-text

A phase-II trial of all trans retinoic acid and low-dose cytosine arabinoside for the treatment of high-risk myelodysplastic syndromes

Annals of Hematology ◽

10.1007/s002770050569 ◽

2000 ◽

Vol 79 (3) ◽

pp. 138-142 ◽

Cited By ~ 19

Author(s):

A. Venditti ◽

A. Tamburini ◽

F. Buccisano ◽

M. T. Scimò ◽

G. Del Poeta ◽

...

Keyword(s):

Retinoic Acid ◽

High Risk ◽

Phase Ii ◽

Myelodysplastic Syndromes ◽

Cytosine Arabinoside ◽

Low Dose ◽

Phase Ii Trial ◽

Trans Retinoic Acid ◽

All Trans Retinoic Acid

Download Full-text

14 A PHASE 2, DOSE-FINDING STUDY OF SOTATERCEPT (ACE-011) IN PATIENTS WITH LOWER-RISK MYELODYSPLASTIC SYNDROMES (MDS) OR NON-PROLIFERATIVE CHRONIC MYELOMONOCYTIC LEUKEMIA (CMML) AND ANEMIA REQUIRING TRANSFUSION

Leukemia Research ◽

10.1016/s0145-2126(15)30015-1 ◽

2015 ◽

Vol 39 ◽

pp. S5-S6 ◽

Cited By ~ 9

Author(s):

R. Komrokji ◽

G. Garcia-Manero ◽

L. Ades ◽

A. Laadem ◽

B. Vo ◽

...

Keyword(s):

Myelodysplastic Syndromes ◽

Lower Risk ◽

Chronic Myelomonocytic Leukemia ◽

Dose Finding ◽

Phase 2 ◽

Finding Study ◽

Dose Finding Study ◽

Myelomonocytic Leukemia

Download Full-text

Treatment of high risk myelodysplastic syndromes with idarubicin and cytosine arabinoside supported by granulocyte-macrophage colony-stimulating factor (GM-CSF)

Leukemia Research ◽

10.1016/0145-2126(95)00169-7 ◽

1996 ◽

Vol 20 (5) ◽

pp. 385-390 ◽

Cited By ~ 20

Author(s):

Theofanis Economopoulos ◽

Efstathios Papageorgiou ◽

Nicholas Stathakis ◽

Maria Constantinidou ◽

Agapi Parharidou ◽

...

Keyword(s):

High Risk ◽

Myelodysplastic Syndromes ◽

Cytosine Arabinoside ◽

Colony Stimulating Factor ◽

Gm Csf ◽

Macrophage Colony Stimulating Factor ◽

Macrophage Colony ◽

Stimulating Factor

Download Full-text